Vinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, Soumyajit Roy, Beverly Chigarira, Arshit Narang, Georges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, Gliceida Galarza Fortuna, Richard Ji, Patrick Campbell, Haoran Li, Neeraj Agarwal, Sumati Gupta, Umang Swami
IMPORTANCE: The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the introduction of effective, novel therapeutic agents. However, outcomes remain poor, and little is known about current treatment approaches and attrition rates for patients with aUC. OBJECTIVES: To delineate evolving treatment patterns and attrition rates in patients with aUC using a US-based patient-level sample. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used patient-level data from the nationwide deidentified electronic health record database Flatiron Health, originating from approximately 280 oncology clinics across the US...
May 1, 2024: JAMA Network Open